Thus, HMGB1 serves as an effective early indicator for predicting the prognosis of patients with bladder cancer, and at the same time, inhibition of HMGB1 may enable bladder cancer patients to obtain greater benefits from systemic therapy. The gene discussed is HMGB1; the disease is urinary bladder carcinoma.